Finally, the study of Kumar et al. [94] opens the prospect of using NGF as a biomarker to also distinguish benign tumors from each other, as breast phyllodes tumors overexpress NGF up to five times more than fibroadenomas tumors. Here, NGF is linked to breast phyllodes tumor.